Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

Fabian J Theis | E. Zeggini | J. Hasenauer | M. Herrmann | M. Hoelscher | A. Thomschke | Mercè Garí | M. Laxy | E. Raimúndez | O. Geisenberger | S. Zange | C. Rothe | K. Strobl | M. Schunk | Peter Pütz | Peter Sothmann | C. Wallrauch | Thorbjörn Zimmer | Verena Thiel | C. Janke | Stefan Hillmann | S. Prückner | R. Rubio-Acero | I. Noreña | R. Leidl | K. Radon | L. Schwettmann | L. Contento | G. Dobler | M. Pritsch | Anna Do | G. Fröschl | I. Kroidl | N. Castelletti | E. Saathoff | J. Durner | Felix Forster | Paul Schandelmaier | Magdalena Lang | A. Kroidl | Marius Gasser | Thomas Zimmermann | M. Pletschette | A. Bakuli | C. Geldmacher | Stefanie Fischer | L. Olbrich | Sacha Horn | Mohamed I. M. Ahmed | J. Guggenbühl | Isabel Klugherz | J. Beyerl | A. Markgraf | C. Hinske | M. Becker | Max Diefenbach | Friedrich Riess | Judith Eckstein | Arlett Heiber | K. Huber | D. Metaxa | Jessica Michelle Guggenbuehl Noller | Anna-Maria Mekota | J. Waibel | P. Mang | Larissa Hofmann | A. Wieser | M. Plank | Anna Brauer | N. Schäfer | Clemens Lang | M. Baumann | Jakob Reich | P. Girl | V. Baldassarre | L. Schneider | S. Winter | Z. Khan | U. Eberle | S. Schultz | Jared Anderson | T. Eser | Yannik Schälte | K. Müller | S. Gauder | I. Paunović | J. Sedlmeier | Julius Raschka | E. Guglielmini | A. Nafziger | Jeni Tang | Julian Ullrich | R. Mayrhofer | Pia Wullinger | R. Le Gleut | Christian J Fuchs | J. Bruger | Jonathan Frese | Kerstin Puchinger | Charlotte Kiani | Felix Lindner | Emad Alamoudi | Marieke Behlen | Rebecca Böhnlein | Vera Britz | Friedrich Caroli | Jana Diekmannshemke | Kristina Gillig | Janna Hoefflin | Michael Höfinger | Ursula Kappl | Hannah Müller | Leonie Pattard | Konstantin Pusl | Niklas Thur | Julia Wolff | A. Zielke | Paulina Diepers | Annika R. P. Schneider | Christina Reinkemeyer | Alina Czwienzek | Elias Golschan | Vitus Grauvogl | Celina Halfmann | Tim Haselwarter | Norah Kreider | E. Lapteva | Alexander Maczka | Paula Matcau | E. Thumser | T. Würfel | Patrick Wustrow | E. Mohr | Luca Heller | Fabian Luppa | L. Gilberg | I. Brand | L. Hillari | Olimbek Bemirayev | Patrick Bitzer | J. Coleman | P. Falk | Manuela Feyereisen | Anslem Haderer | Marlene Hannes | Lena Hartinger | Alejandra Hernandez | Antonia Keßler | Johanna Kresin | Leopold Liedl | Xhovana Lucaj | C. Pleimelding | Viktoria Ruci | Benedikt Schluse | Alba Soler | Vincent Vollmayr | Emilia von Lovenberg | Jonathan von Lovenberg | S. Thiesbrummel | Lea Zuche | Pablo Gutierrez | T. Hofberger | Volker Fingerle | F. Déak | Silvan Lange | Heike Fensterseifer | Emad Jared Valeria Maximilian Marc Franziska Marieke Ol Alamoudi Anderson Baldassarre Baumann Becker | Franziska Bednarski | Franziska Bünz | Raffaela Geier | Keisha Gezgin | Lilian Karger | Pratik Kunder | E. Lucke | Nathalia Nascimento | K. Niermeyer | Sophia Nikolaides | Viona Poll | Linda Sintu-Sempta | Aida Strüber | Laura Strüber | C. Vos | Nikolas Weigl | Roman Wölfl

[1]  S. Zeger,et al.  Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.

[2]  E. Zeggini,et al.  The interplay of viral loads, clinical presentation, and serological responses in SARS-CoV-2 – Results from a prospective cohort of outpatient COVID-19 cases , 2022, Virology.

[3]  H. Scheiblauer,et al.  Antibody response to SARS-CoV-2 for more than one year − kinetics and persistence of detection are predominantly determined by avidity progression and test design , 2021, Journal of Clinical Virology.

[4]  L. Abu-Raddad,et al.  BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar , 2021, Nature Medicine.

[5]  Y. Kreiss,et al.  Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months , 2021, The New England journal of medicine.

[6]  J. Hasenauer,et al.  Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2 , 2021, The Journal of general virology.

[7]  John P. Moore,et al.  Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination , 2021, Science advances.

[8]  L. Abu-Raddad,et al.  Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.

[9]  B. Mizrahi,et al.  Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine , 2021, Nature Communications.

[10]  M. Lipsitch,et al.  Covid-19 Breakthrough Infections in Vaccinated Health Care Workers , 2021, The New England journal of medicine.

[11]  J. Münch,et al.  Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination , 2021, Nature Medicine.

[12]  M. Hoelscher,et al.  Vaccine breakthrough infection and onward transmission of SARS-CoV-2 Beta (B.1.351) variant, Bavaria, Germany, February to March 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  F. Krammer.  A correlate of protection for SARS-CoV-2 vaccines is urgently needed , 2021, Nature Medicine.

[14]  A. Hayward,et al.  Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 , 2021, The Lancet.

[15]  J. Vekemans,et al.  Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[16]  E. Zeggini,et al.  In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients , 2021, Infectious Diseases and Therapy.

[17]  D. Swerdlow,et al.  Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data , 2021, The Lancet.

[18]  R. Darnell,et al.  Vaccine Breakthrough Infections with SARS-CoV-2 Variants , 2021, The New England journal of medicine.

[19]  K. Makar,et al.  WHO International Standard for anti-SARS-CoV-2 immunoglobulin , 2021, The Lancet.

[20]  Ross J. Harris,et al.  Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers , 2021, Journal of Infection.

[21]  M. Hernán,et al.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.

[22]  D. Weir,et al.  SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study , 2021, The Lancet Respiratory Medicine.

[23]  Jerome H. Kim,et al.  Looking beyond COVID-19 vaccine phase 3 trials , 2021, Nature Medicine.

[24]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[25]  D. Stuart,et al.  Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers , 2020, The New England journal of medicine.

[26]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[27]  R. Tibshirani,et al.  Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome , 2020, Science Immunology.

[28]  K. Klingel,et al.  Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients , 2020, Viruses.

[29]  P. Bieniasz,et al.  Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients , 2020, The Journal of infectious diseases.

[30]  M. Malim,et al.  Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans , 2020, Nature Microbiology.

[31]  M. Dake,et al.  Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity , 2020, Immunity.

[32]  M. Veldhoen,et al.  Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset , 2020, medRxiv.

[33]  A. Gylfason,et al.  Humoral Immune Response to SARS-CoV-2 in Iceland , 2020, The New England journal of medicine.

[34]  Guozhong Zhang,et al.  Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19 , 2020, Signal Transduction and Targeted Therapy.

[35]  Otto O. Yang,et al.  Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19 , 2020, The New England journal of medicine.

[36]  X. Tang,et al.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.

[37]  Mike Clarke,et al.  A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.

[38]  Sittichai Tantipasawasin.  Coronavirus disease (COVID-19) Pandemic , 2020 .

[39]  X. Tang,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.